MX366204B - Pronostico medico y prediccion de la respuesta al tratamiento utilizando multiples actividades de la trayectoria de señalizacion celular. - Google Patents
Pronostico medico y prediccion de la respuesta al tratamiento utilizando multiples actividades de la trayectoria de señalizacion celular.Info
- Publication number
- MX366204B MX366204B MX2015014847A MX2015014847A MX366204B MX 366204 B MX366204 B MX 366204B MX 2015014847 A MX2015014847 A MX 2015014847A MX 2015014847 A MX2015014847 A MX 2015014847A MX 366204 B MX366204 B MX 366204B
- Authority
- MX
- Mexico
- Prior art keywords
- pathway
- wnt
- prediction
- signalling pathway
- treatment response
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- G16B5/20—Probabilistic models
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physiology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Probability & Statistics with Applications (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Data Mining & Analysis (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
Abstract
La presente invención se refiere a un método para determinar una puntuación del riesgo que indica un riesgo de que un evento clínico ocurrirá dentro de un cierto período de tiempo. La puntuación del riesgo se basa al menos en parte en una combinación de actividades inferidas de dos o más trayectorias de señalización celular en un tejido y/o células y/o fluido corporal de un sujeto. Las trayectorias de señalización celular comprenden una trayectoria Wnt, una trayectoria ER, una trayectoria HH, y/o una trayectoria AR. La puntuación del riesgo se define de tal forma que el riesgo indicado de que ocurrirá un evento clínico dentro de un cierto período de tiempo se reduce con un PER en aumento y aumenta con un max (Pwnt, PHH) en aumento, en donde PER, Pwnt, y PHH denotan la actividad inferida de la trayectoria ER, la trayectoria Wnt, y la trayectoria HH, respectivamente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13165471 | 2013-04-26 | ||
| PCT/EP2014/058326 WO2014174003A1 (en) | 2013-04-26 | 2014-04-24 | Medical prognosis and prediction of treatment response using multiple cellular signalling pathway activities |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015014847A MX2015014847A (es) | 2016-03-11 |
| MX366204B true MX366204B (es) | 2019-07-02 |
Family
ID=48182831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015014847A MX366204B (es) | 2013-04-26 | 2014-04-24 | Pronostico medico y prediccion de la respuesta al tratamiento utilizando multiples actividades de la trayectoria de señalizacion celular. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11309059B2 (es) |
| EP (2) | EP3372695B1 (es) |
| JP (1) | JP6603208B2 (es) |
| KR (1) | KR102256141B1 (es) |
| CN (1) | CN105121665B (es) |
| AU (1) | AU2014259459B2 (es) |
| BR (1) | BR112015026736A2 (es) |
| CA (1) | CA2909991A1 (es) |
| MX (1) | MX366204B (es) |
| RU (1) | RU2718647C2 (es) |
| WO (1) | WO2014174003A1 (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2909991A1 (en) | 2013-04-26 | 2014-10-30 | Koninklijke Philips N.V. | Medical prognosis and prediction of treatment response using multiple cellular signalling pathway activities |
| EP3013986B1 (en) | 2014-01-03 | 2016-11-16 | Koninklijke Philips N.V. | Assessment of the pi3k cellular signaling pathway activity using mathematical modelling of target gene expression |
| WO2016062891A1 (en) | 2014-10-24 | 2016-04-28 | Koninklijke Philips N.V. | ASSESSMENT OF TGF-β CELLULAR SIGNALING PATHWAY ACTIVITY USING MATHEMATICAL MODELLING OF TARGET GENE EXPRESSION |
| CN108064380A (zh) | 2014-10-24 | 2018-05-22 | 皇家飞利浦有限公司 | 使用多种细胞信号传导途径活性的医学预后和治疗反应的预测 |
| JP7065609B6 (ja) | 2014-10-24 | 2022-06-06 | コーニンクレッカ フィリップス エヌ ヴェ | 複数の細胞シグナル伝達経路活性を用いる治療応答の医学的予後及び予測 |
| EP3334837B1 (en) | 2015-08-14 | 2020-12-16 | Koninklijke Philips N.V. | Assessment of nfkb cellular signaling pathway activity using mathematical modelling of target gene expression |
| US20190128899A1 (en) * | 2016-06-13 | 2019-05-02 | Koninklijke Philips N.V. | Method for inferring activity of a transcription factor of a signal transduction pathway in a subject |
| WO2018152240A1 (en) * | 2017-02-14 | 2018-08-23 | The Regents Of The University Of Colorado, A Body Corporate | Methods for predicting transcription factor activity |
| EP3431582A1 (en) | 2017-07-18 | 2019-01-23 | Koninklijke Philips N.V. | Cell culturing materials |
| EP3692170A1 (en) | 2017-10-02 | 2020-08-12 | Koninklijke Philips N.V. | Determining functional status of immune cells types and immune response |
| EP3461915A1 (en) | 2017-10-02 | 2019-04-03 | Koninklijke Philips N.V. | Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression |
| EP3502279A1 (en) | 2017-12-20 | 2019-06-26 | Koninklijke Philips N.V. | Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression |
| CN113316823A (zh) * | 2018-09-29 | 2021-08-27 | 豪夫迈·罗氏有限公司 | 基于多模态机器学习的临床预测器 |
| US11674185B2 (en) * | 2019-05-03 | 2023-06-13 | Koninklijke Philips N.V. | Methods of prognosis in high-grade serous ovarian cancer |
| EP3739588A1 (en) | 2019-05-13 | 2020-11-18 | Koninklijke Philips N.V. | Assessment of multiple signaling pathway activity score in airway epithelial cells to predict airway epithelial abnormality and airway cancer risk |
| WO2021022365A1 (en) * | 2019-08-02 | 2021-02-11 | Intellijoint Surgical Inc. | Systems and methods to collaborate, to train an expert system and to provide an expert system |
| EP3882363A1 (en) | 2020-03-17 | 2021-09-22 | Koninklijke Philips N.V. | Prognostic pathways for high risk sepsis patients |
| KR102565378B1 (ko) * | 2020-03-23 | 2023-08-10 | 단국대학교 산학협력단 | 유방암 호르몬 수용체의 상태 예측을 위한 바이오 마커 |
| EP3978628A1 (en) | 2020-10-01 | 2022-04-06 | Koninklijke Philips N.V. | Prognostic pathways for viral infections |
| WO2021209567A1 (en) | 2020-04-16 | 2021-10-21 | Koninklijke Philips N.V. | Prognostic pathways for viral infections |
| EP3940704A1 (en) | 2020-07-14 | 2022-01-19 | Koninklijke Philips N.V. | Method for determining the differentiation state of a stem cell |
| EP3960875A1 (en) * | 2020-08-28 | 2022-03-02 | Koninklijke Philips N.V. | Pcr method and kit for determining pathway activity |
| EP3965119A1 (en) | 2020-09-04 | 2022-03-09 | Koninklijke Philips N.V. | Methods for estimating heterogeneity of a tumour based on values for two or more genome mutation and/or gene expression related parameter, as well as corresponding devices |
| EP3974540A1 (en) | 2020-09-25 | 2022-03-30 | Koninklijke Philips N.V. | Method for predicting immunotherapy resistance |
| KR102189142B1 (ko) * | 2020-10-15 | 2020-12-09 | 서울대학교병원 | 만성신장질환의 악화 예측 마커로서의 snp 및 이의 이용 |
| EP4015651A1 (en) | 2020-12-17 | 2022-06-22 | Koninklijke Philips N.V. | Treatment prediction and effectiveness of anti-tnf alpha treatment in ibd patients |
| EP4039825A1 (en) | 2021-02-09 | 2022-08-10 | Koninklijke Philips N.V. | Comparison and standardization of cell and tissue culture |
| WO2022189530A1 (en) | 2021-03-11 | 2022-09-15 | Koninklijke Philips N.V. | Prognostic pathways for high risk sepsis patients |
| CN114410667B (zh) * | 2021-12-31 | 2022-10-11 | 广东省科学院动物研究所 | 一种鞍带石斑鱼znrf3基因及其编码的蛋白和应用 |
| KR102508252B1 (ko) * | 2022-01-11 | 2023-03-09 | 주식회사 볼츠만바이오 | 생체신호전달 네트워크 모델의 학습방법 및 이를 위한 장치 |
| CN114524872A (zh) * | 2022-03-09 | 2022-05-24 | 广州诺诚生物技术研发有限公司 | 一种用于乳腺癌检测的单克隆抗体及其试剂盒 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060235255A1 (en) | 2005-04-15 | 2006-10-19 | Gartside Robert J | Double bond hydroisomerization process |
| EP1910564A1 (en) * | 2005-05-13 | 2008-04-16 | Duke University | Gene expression signatures for oncogenic pathway deregulation |
| RU2376372C2 (ru) * | 2007-04-03 | 2009-12-20 | Государственное учреждение Научно-исследовательский институт медицинской генетики Томского научного центра Сибирского отделения Российской академии медицинских наук | Способ генетической диагностики подверженности к сердечно-сосудистым заболеваниям |
| WO2010144358A1 (en) | 2009-06-08 | 2010-12-16 | Singulex, Inc. | Highly sensitive biomarker panels |
| RU2013140708A (ru) * | 2011-02-04 | 2015-03-10 | Конинклейке Филипс Н.В. | Способ для оценки потока информации в биологических сетях |
| EP2549399A1 (en) * | 2011-07-19 | 2013-01-23 | Koninklijke Philips Electronics N.V. | Assessment of Wnt pathway activity using probabilistic modeling of target gene expression |
| WO2013084144A1 (en) | 2011-12-08 | 2013-06-13 | Koninklijke Philips Electronics N.V. | Semiconductor light emitting device with thick metal layers |
| AU2013368945B2 (en) | 2012-12-26 | 2020-01-23 | Innosign B.V. | Assessment of cellular signaling pathway activity using linear combination(s) of target gene expressions |
| CA2909991A1 (en) | 2013-04-26 | 2014-10-30 | Koninklijke Philips N.V. | Medical prognosis and prediction of treatment response using multiple cellular signalling pathway activities |
-
2014
- 2014-04-24 CA CA2909991A patent/CA2909991A1/en not_active Abandoned
- 2014-04-24 AU AU2014259459A patent/AU2014259459B2/en not_active Ceased
- 2014-04-24 US US14/785,400 patent/US11309059B2/en active Active
- 2014-04-24 WO PCT/EP2014/058326 patent/WO2014174003A1/en active Application Filing
- 2014-04-24 JP JP2016509460A patent/JP6603208B2/ja active Active
- 2014-04-24 CN CN201480023555.6A patent/CN105121665B/zh active Active
- 2014-04-24 RU RU2015150464A patent/RU2718647C2/ru active
- 2014-04-24 EP EP18162835.5A patent/EP3372695B1/en active Active
- 2014-04-24 KR KR1020157033676A patent/KR102256141B1/ko active IP Right Grant
- 2014-04-24 MX MX2015014847A patent/MX366204B/es active IP Right Grant
- 2014-04-24 BR BR112015026736A patent/BR112015026736A2/pt active Search and Examination
- 2014-04-24 EP EP14721293.0A patent/EP2989211B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2909991A1 (en) | 2014-10-30 |
| BR112015026736A2 (pt) | 2017-07-25 |
| US20160110494A1 (en) | 2016-04-21 |
| WO2014174003A1 (en) | 2014-10-30 |
| EP2989211B1 (en) | 2018-06-13 |
| EP3372695B1 (en) | 2020-09-09 |
| RU2015150464A (ru) | 2017-06-02 |
| MX2015014847A (es) | 2016-03-11 |
| AU2014259459A1 (en) | 2015-12-17 |
| EP2989211A1 (en) | 2016-03-02 |
| US11309059B2 (en) | 2022-04-19 |
| KR102256141B1 (ko) | 2021-05-27 |
| JP6603208B2 (ja) | 2019-11-06 |
| CN105121665B (zh) | 2019-11-26 |
| JP2016519926A (ja) | 2016-07-11 |
| RU2718647C2 (ru) | 2020-04-10 |
| EP3372695A1 (en) | 2018-09-12 |
| KR20160003124A (ko) | 2016-01-08 |
| AU2014259459B2 (en) | 2020-03-26 |
| CN105121665A (zh) | 2015-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX366204B (es) | Pronostico medico y prediccion de la respuesta al tratamiento utilizando multiples actividades de la trayectoria de señalizacion celular. | |
| MX2016004899A (es) | Metodos para evaluar el desarrollo de bebes y niños via rastreo ocular. | |
| MX2016005159A (es) | Metodos de diagnostico y tratamiento de trastornos eosinofilicos. | |
| WO2016094904A8 (en) | Methods of measuring erbb signaling pathway activity to diagnose and treat cancer patients | |
| MY174894A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation | |
| EP3043875A4 (en) | Method to determine body's physiological response to physical exercise for assessing readiness and to provide feedback, and system for implementing the method | |
| GEP20166449B (en) | Treatment of pain associated with dislocation of basal endometrium | |
| WO2014152754A3 (en) | Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens | |
| IN2014KN02687A (es) | ||
| WO2014125378A3 (en) | Systems and methods for managing and dynamically predicting respiratory episodes | |
| WO2014159926A3 (en) | Medical treatment management | |
| WO2015067710A3 (en) | Tyrp1, a natural mirna sponge, and its use in managing human melanoma aggressiveness | |
| EP2972377A4 (en) | SYSTEMS AND METHODS EMPLOYING HUMAN STEM CELL MARKERS FOR THE DETECTION, DIAGNOSIS AND TREATMENT OF TUMOR CELLS IN CIRCULATION | |
| WO2014179487A3 (en) | Health care communications management system and method of use | |
| WO2014055556A3 (en) | System and method for automatically generating a historical health trend graph for a patient | |
| BR112014019274A2 (pt) | métodos relacionados ao tratamento de doenças e distúrbios inflamatórios | |
| UA45411U (ru) | Способ прогнозирования тяжести течения лептоспироза | |
| UA99717U (uk) | Спосіб прогнозування досягнення цільового артеріального тиску у хворих з артеріальною гіпертензією та цукровим діабетом | |
| EA201690217A1 (ru) | Способ и диагностический набор для контроля рассеянного склероза (pc) | |
| D’Alo | Chloramine-T Anaphylaxis: case report | |
| BBaallaassuubbrraammaanniiaann et al. | Combinatorial treatment with epigenetic modifiers inhibits thrombin-induced eNOS/RhoA signaling and restores AJ integrity (1176.7) | |
| Shimokawaji et al. | Pre-Treatment With Clarithromycin Modulates LPS-Stimulated IL-8 Secretion In Association With Modulation Of IL-8 MRNA And ERK In Normal Human Bronchial Epithelial Cells | |
| WO2018222432A8 (en) | A predictive biomarker for let-7 microrna-based therapeutics for the treatment of human cancer | |
| UA83553U (ru) | Способ прогнозирования развития рецидивирующего течения пиелонефрита | |
| Bivens et al. | Attachment, Oxytocin, and Cortisol Reactivity in Young Women after Romantic Break-up |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |